Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06654817
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-10-14
Brief Title:
Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Evaluation of Combination Therapy with Ofatumumab and Systemic Corticosteroids for Pemphigus a Multi-center Cohort Study
Status:
COMPLETED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A prospective cohort study was conducted following patients for 36 weeks from January 1 2023 to April 30 2024 Patients meeting the diagnostic criteria were nonrandomly grouped based on screening results The primary endpoints were time to disease control and skin healing Secondary endpoints included complete remission rates relapse rates corticosteroid doses pemphigus disease area index PDAI dermatology life quality index DLQI visual analogue scale VAS pain scores CD19 B cell percentages desmoglein-specific antibodies and adverse events
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None